EHA 2023: Kura Oncology’s menin inhibitor ziftomenib shows impressive Phase I results
Pharmaceutical Technology
JUNE 13, 2023
As for safety, 85% had at least one Grade 3 or higher treatment-emergent adverse event (TEAE). According to GlobalData’s analyst consensus forecast, global sales for ziftomenib will reach $255m by 2029. Kura faces competition in the menin inhibitor market as the therapy is being developed to treat various indications.
Let's personalize your content